Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼Ò¾Æ ÁøÁ¤ Ä¡·á ½Ã ±¸°­ Á¡¸· ÇÏ¿Í ºñÁ¡¸· Midazolam Åõ¿©ÀÇ Çൿ ¹ÝÀÀ ºñ±³

Comparison of Behavioral Response between Intranasal and Submucosal Midazolam Adminstration

´ëÇѼҾÆÄ¡°úÇÐȸÁö 2008³â 35±Ç 3È£ p.427 ~ 436
±èÀ±Èñ, Á¤»óÇõ, ¹é±¤¿ì,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÀ±Èñ ( Kim Yoon-Hee ) - ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐ ¸ñµ¿º´¿ø Ä¡°úÇб³½Ç
Á¤»óÇõ ( Jung Sang-Hyuk ) - ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐ ¿¹¹æÀÇÇб³½Ç
¹é±¤¿ì ( Baek Kwang-Woo ) - ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐ ¿¹¹æÀÇÇб³½Ç

Abstract

ÁøÁ¤¹ýÀ» ÀÌ¿ëÇÑ ¼Ò¾ÆȯÀÚÀÇ Ä¡°úÄ¡·á ½Ã chloral hydrate¿Í hydroxyzineÀ» º¹¿ë ÈÄ Ãß°¡·Î midazolamÀ» ºñÁ¡¸·³»·Î ºÐ¹«ÇÏ´Â °Í°ú ±¸°­ Á¡¸· ÇÏ·Î ÁÖ»çÇßÀ» ¶§ Çൿ ¹ÝÀÀ°ú ÁøÁ¤ È¿°ú¿¡ ´ëÇØ ºñ±³ÇÏ°íÀÚ ÇÏ¿´´Ù. ¹Ì±¹ ¸¶Ãë°úÇÐȸ ½Åüµî±Þ I±Þ (ASAI)À̸ç, ÇùÁ¶°¡ ¾È µÇ´Â 24-72 °³¿ù ¼Ò¾Æ ȯÀÚ Áß ÁøÁ¤¹ýÀ» ÅëÇØ 2°³ Ä¡¾Æ ÀÌ»óÀÇ º¸Á¸ Ä¡·á ¹× ¹ßÄ¡ Ä¡·á¸¦ ¹ÞÀº 33¸íÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù. ¸ðµç ȯÀÚ´Â chloral hydrate 50 mg/kg ¿Í hydroxyzine 1 mg/kg º¹¿ëÇÏ¿´´Ù. 45ºÐ ÈÄ ÇÑ ±ºÀº ºñ°­³»·Î midazolam 0.2 mg/kg À» Ãß°¡ Åõ¿©ÇÏ¿´°í ´Ù¸¥ ±ºÀº ±¸°­ Á¡¸· ÇÏ midazolam 0.2mg/kg À» ÁÖ»çÇÏ¿´´Ù. Ä¡·áÇÏ´Â µ¿¾È µÎ ±º ¸ðµÎ 50 % nitrous oxide ¸¦ À¯ÁöÇÏ¿´´Ù. ¸Æ¹Ú »ê¼Ò °èÃø±â¿Í È£±â¸» ÀÌ»êȭź¼Ò ºÐ¾Ð ÃøÁ¤±â¸¦ ÀÌ¿ëÇÏ¿© »ê¼Ò Æ÷È­µµ, ¸Æ¹Ú¼ö, È£Èí¼ö, È£±â¸» ÀÌ»êȭź¼Ò ºÐ¾ÐÀ» ±â·ÏÇÏ¿´´Ù. Çൿ ¹ÝÀÀÀº Quiet(Q), Crying(C), Movement(M) ±×¸®°í Struggling(S)¸¦ ÀÌ¿ëÇÏ¿© ÃÑ 40ºÐ µ¿¾È ¸Å 2ºÐ¸¶´Ù ±â·ÏÇÏ°í ¸ðµç ÁøÁ¤ Ä¡·á °úÁ¤Àº ºñµð¿À·Î ÃÔ¿µÇÏ¿´´Ù. ¸ðµç ÀÚ·á´Â chi-sqaure test¿Í two sample independent t-test¸¦ »ç¿ëÇÏ¿© ºÐ¼®ÇÏ¿´´Ù. µÎ ±º°£ÀÇ Æò±Õ µµÀÔ ½Ã°£°ú ÃÖ´ë Ä¡·á ½Ã°£Àº Åë°èÇÐÀûÀ¸·Î À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾ú´Ù. ¶ÇÇÑ È°·Â »ý¡Èĵµ ¸ðµÎ Á¤»ó ¹üÀ§ÀÌ¸ç µÎ ±º »çÀÌ¿¡ Åë°èÇÐÀûÀ¸·Î À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾ú´Ù. Çൿ ¹ÝÀÀ ºñ±³¿¡¼­´Â Ä¡·á ½ÃÀÛ 10ºÐ µ¿¾È ºñ°­³» Åõ¿© ±ºÀÌ Á¡¸· ÇÏ Åõ¿© ±ºº¸´Ù °³¼±µÈ Çൿ ¹ÝÀÀÀ» º¸¿´´Ù(P<0.05). Ä¡·á ½ÃÀÛ 10ºÐ ÀÌÈÄ¿¡´Â µÎ ±º»çÀÌÀÇ Çൿ ¹ÝÀÀ¿¡¼­ À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾ú´Ù. ÀÌ ¿¬±¸´Â chloral hydrate ¿Í hydroxyzine º¹¿ë ÈÄ nitrous oxide 50%·Î À¯ÁöÇÏ´Â ÁøÁ¤¹ý¿¡ ºñ°­³»·Î midazolamÀ» Ãß°¡ Åõ¿©ÇÏ´Â °ÍÀº Á¡¸· ÇÏ·Î Ãß°¡ Åõ¿©¿Í À¯»çÇÑ ÁøÁ¤ È¿°ú¸¦ °¡Áø´Ù. ¶ÇÇÑ ºñ°­³» midazolam Ãß°¡ Åõ¿©ÇÏ´Â °ÍÀº ±¸°­ Á¡¸· ÇÏ·Î Ãß°¡ Åõ¿©ÀÇ ÀåÁ¡À» °¡Áö¸é¼­µµ ºñħ½ÀÀûÀÌ°í »ó´ëÀûÀ¸·Î ÅëÁõÀÌ Àû´Ù´Â ÀÌÁ¡ÀÌ ÀÖ´Ù. ±×·¯¹Ç·Î ºñ°­³» midazolam Ãß°¡ Åõ¿©´Â ħ½ÀÀûÀÎ ±¸°­ Á¡¸· ÇÏ Ãß°¡ Åõ¿©¸¦ ´ëüÇÒ ¸¸ÇÑ ¹æ¹ýÀÌ´Ù.

Purpose. The objective of this study was to evaluate the behavioral response and assess the effectiveness of additional intranasal (IN) and submucosal (SM) administration of midazolam during pediatric sedation for dental procedure. Material and methods. Thirty-three cases of healthy (ASA¥°), uncooperative children aged from 24 to 72 month old at pediatric dental clinic of Ewha Womans University Hospital were selected for this study. Children received oral chloral hydrate 50 mg/kg with hydroxyzine 1.0 mg/kg. After waiting for 45 minutes, midazolam 0.2 mg/kg was administrated via IN route and via SM route randomly maintaining 50% of . A pulse oximeter and a capnograph were used for measuring vital signs (, PR, RR, ) throughout the sedation. Behavioral response was evaluated as Quiet (Q), Crying (C), Movement (M) or Struggling (S) in every 2 minutes for 40 minutes. Results. There were also no statistically significant differences in vital signs of the two groups. The behavioral response for the first ten minutes during sedation was a statistically significant difference (P < 0.05) between the two groups. After the first ten minutes, it was revealed that there was no significant difference. Conclusion. This study demonstrated that the addition of IN midazolam to the combination of oral chloral hydrate with hydroxyzine and nitrous oxide/oxygen inhalation is as safe and effective as that of SM midazolam in pediatric sedation for dental procedure.

Å°¿öµå

ÁøÁ¤¹ý;Á¡¸·ÇÏ ¹Ì´ÙÁ¹¶÷;ºñ°­³» ¹Ì´ÙÁ¹¶÷;Å©·Î¶ö ÇÏÀ̵巹ÀÌÆ®
Sedation;Submucosal midazolam;Intranasal midazolam;Chloral hydrate

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI